APA (7th ed.) Citation

McKenzie, A., Roberts, A., Malandkar, S., Feuersenger, H., Panousis, C., & Pawaskar, D. (2021). A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous Garadacimab (CSL312) in Healthy Subjects. Journal of allergy and clinical immunology, 147(2), AB137. https://doi.org/10.1016/j.jaci.2020.12.498

Chicago Style (17th ed.) Citation

McKenzie, Andrew, Anthony Roberts, Sourabh Malandkar, Henrike Feuersenger, Con Panousis, and Dipti Pawaskar. "A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous Garadacimab (CSL312) in Healthy Subjects." Journal of Allergy and Clinical Immunology 147, no. 2 (2021): AB137. https://doi.org/10.1016/j.jaci.2020.12.498.

MLA (9th ed.) Citation

McKenzie, Andrew, et al. "A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous Garadacimab (CSL312) in Healthy Subjects." Journal of Allergy and Clinical Immunology, vol. 147, no. 2, 2021, p. AB137, https://doi.org/10.1016/j.jaci.2020.12.498.